Bioadaptives, Inc.
BioAdaptives, Inc. is a U.S.-based nutraceutical and medical-device marketing company focused on natural plant, fungi, algal, and cyanobacteria-based products. The company develops, markets, and distributes wellness products aimed at humans and animals, with emphasis on pain relief, anti-viral support, anti-aging, nootropics, weight control, and relaxation. It also markets the FDA-cleared Lung Flute™ device and has expanded its product rights through a 2024 transaction to support broader commercialization. BioAdaptives currently operates with a very lean structure, relying heavily on digital marketing, affiliates, telehealth partnerships, and outsourced support rather than in-house manufacturing.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNatural supplement products based on plant, fungi, algal, and cyanobacteria ingredients for wellness use.
Commercialization and distribution of the Lung Flute™ and related respiratory wellness devices.
Online marketing and sales activities that convert health-conscious consumers through the company website and social channels.
Customers
BioAdaptives sells primarily to health-conscious consumers who buy supplements for wellness, relaxation, weight control, anti-aging, and pain relief support. A second important customer group is telehealth platforms and their participants, where the company positions its products as companion or standalone wellness options. The company also targets channel buyers and end users in medical communities, pharmacies, gyms, athletic clubs, and senior communities for the Lung Flute™ and related products. Its affiliate and influencer model suggests that purchase decisions are often driven by trust, social proof, and online discovery rather than traditional retail distribution.
Individuals purchasing supplements online for anti-aging, relaxation, pain relief, nootropics, and general wellness support.
Participants in virtual care ecosystems who are offered BioAdaptives products as companion or standalone wellness solutions.
Clinics, pharmacies, and medical communities that may adopt the Lung Flute™ for respiratory wellness use cases.
Gyms, athletic clubs, and senior communities targeted for wellness and respiratory support products.
Strategy
BioAdaptives is repositioning its product line and stated that it began introducing new products in the second quarter of 2025. The company’s near-term strategy is to increase marketing spend, build sales volume, and use direct-to-consumer, affiliate, and telehealth channels to create repeatable demand. It is also trying to broaden the commercial footprint of the Lung Flute™ beyond direct sales into medical, pharmacy, fitness, and senior-care channels. Because the business is capital constrained, management expects growth to depend on equity financing, selective acquisitions, and outsourced execution rather than internal manufacturing buildout.
The company is trying to refresh its offering mix to improve relevance and sales traction in a crowded supplement market.
Revenue depends on converting online traffic and affiliate reach into sales, so marketing effectiveness is central to growth.
Broader distribution could diversify revenue away from pure DTC supplement sales and improve product credibility.
The company needs external funding to support operations, inventory, and growth initiatives while remaining a going concern.
Geography
BioAdaptives is headquartered in Las Vegas, Nevada, and operates as a U.S.-based company. The available filings do not provide a country-by-country revenue split, but management states it intends to expand sales both in the United States and internationally. Its sourcing model is global, with active ingredients obtained worldwide from suppliers that emphasize compliance and sustainable agricultural practices. Because the company relies on digital marketing and third-party channels, geographic reach is more about market access and sourcing flexibility than owned physical infrastructure.
Risks
BioAdaptives faces substantial going-concern risk because its business model requires ongoing financing to fund marketing, inventory, and public-company costs. The company has limited operating scale, minimal staffing, and no direct manufacturing capability for medical devices, which increases dependence on third parties and working capital availability. Its supplement business also carries regulatory risk because product claims must avoid drug-like or disease-cure language, and any compliance misstep could restrict marketing or trigger enforcement. More broadly, the company is exposed to intense competition in the wellness and supplement market, customer acquisition volatility in digital channels, and execution risk around affiliate quality, telehealth partnerships, and product reformulation.
Management states that future operations likely require equity issuance, debt increases, or both, and there is substantial doubt about the company's ability to continue as a going concern.
The company must avoid health, drug, or disease-cure claims for its nutraceutical products, and misstatements could affect its ability to market products.
Sales depend heavily on DTC digital ads, affiliates, and social media, which can be volatile and expensive to scale.
Exposure: Customer acquisition and conversion rates
Active ingredients are sourced worldwide from external suppliers, creating exposure to quality, availability, and compliance issues.
The company does not expect to build direct manufacturing capability and must rely on purchased finished products and licensing arrangements.
Exposure: Lung Flute™ distribution and related device revenue
Accounting
Judgemental itemsSmall changes in shipment timing or channel fulfillment can swing reported revenue materially when sales are low.
Impact: Quarterly revenue and gross profit volatility
The company carries inventory and has used stock issuances tied to inventory purchases, so valuation and obsolescence assumptions matter.
Impact: Gross margin, current assets, and write-down risk
Issuances of common and preferred stock for debt conversion, stock payable, licenses, and inventory affect capital structure and reported financing activity.
Impact: Dilution, equity balances, and cash flow interpretation
Management's financing assumptions influence whether assets and liabilities are presented on a liquidation or going-concern basis.
Impact: Balance-sheet classification and investor assessment of solvency
Similar listed companies
Publicly listed companies with a comparable business focus.
BioAge Labs, Inc.
BIOA · Pharmaceutical Preparations
Beyond Air, Inc.
XAIR · Surgical & Medical Instruments & Apparatus
Adaptive Biotechnologies Corp
ADPT · Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology.
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
Biohaven Ltd.
BHVN · Pharmaceutical Preparations
Bio Essence Corp
BIOE · Pharmaceutical Preparations
Bio Essence Corp is a California-based holding company whose operating history has centered on health supplements and OEM manufacturing/distribution services.
Last updated: 11/08/2026